

RECEIVED **CENTRAL FAX CENTER**

MAY 1 9 2004



1776 K STREET NW WASHINGTON, DC 20006

14:47

PHONE 202.719.7000 FAX 202.719.7049

Facsimile

PHONE NUMBER **FAX NUMBER** TO 703-872-9306 U.S. Patent and Trademark Office

FROM	Mary K. Drake	PHONE NUMBER	202.719.3258	
DATE	May 19, 2004	PAGES TO FOLLOW	5	
USER NUMBER	1991	CLIENT NUMBER	80375.0021	

MESSAGE:

RE: APPL. NO. 10/724,225

FILED: DECEMBER 1, 2003

TITLE: "ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE PROTEIN MDM2, AND USE THEREOF IN THE TREATMENT OF CANCERS"

EXAMINER: UNASSIGNED

ART UNIT: 1614

CONFIRMATION NO.: 9762

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this Information Disclosure Statement is being facsimile transmitted to the United States Patent and Trademark Office on May 19, 2004.

Confidentiality Note: The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the Intended recipient, you are hereby notified that any dissemination, distribution or copy of this facsimile message is strictly prohibited. If you have received this message in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. Thank you.

Please contact Mary Drake at 202.719.3258 if you do not receive this facsimile in its entirety.

MAY 1 9 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAI

Appl. No.

10/724,225

Confirmation No.: 9762

Applicant

Bruno TOCQUE, et al.

Filed

December 1, 2003

TC/A.U.

1614

Examiner

Unassigned

Docket No.

ST95050-US/A

Customer No.

29693

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The subject application is a Divisional Application of U.S. Application No. 09/029,327 filed on March 23, 1998. In accordance with 37 C.F.R. § 1.98(d), patent documents and published articles which were cited in the prior application are listed on the accompanying Forms SB/08 and PTO-892, but copies of these documents are not enclosed as they were provided in the prior application.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and/or within three months of the filing date of the application. It is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-1129.

Appl. No. 10/724,225 Information Disclosure Statement dated May 19, 2004

While the information and references disclosed in this Information Disclosure Statement are submitted pursuant to 37 C.F.R. § 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to is "prior art" to this invention. Applicants reserve the right to contest the "prior art" status of any information submitted or asserted against the application.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information

Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. This Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed documents and information.

Dated:

May 19, 2004

Respectfully submitted,

WILEY REIN & FIELDING LLP

BV

David J. Kulik

WILEY REIN & FIELDING LLP Attn: Patent Administration

1776 K Street, N.W.

Washington, D.C. 20006
Telephone: 202.719.7000
Facsimile: 202.719.7049

05/19/	2004	14	1:47	WILEY	, REIN	& FIELDIN	IG → USPTO			NO.392	
1174	يم لؤ يُن	8						-		;	
1.5	Řπtűl? peaph	2:	, !	fe this box	.	*				. PTO/SB/08A (h 09/30/98, OMB 0851- ARTMENT OF COMME	0031
1449A/P	TÖ	5.4		U.S. Dep	artment	of Commerce	Complete if Known				
	•			Patent a	nd Trade	mark Office	Application Numb	per	09/029	327	
l i	JST (OF P	RIOR	ART CI	TED E	BY	Filing Date March			3, 1998	
			APPLI				First Named Inve	ntor	Tocque	e et al.	
ľ	(us	e as m	any shee	ets as nece	ssary)		Group Art Unit	1635			
		, . <u></u> .,					Examiner Name		KLO	courciers	
Shee	t		1	of		2	Attorney Docket	Number	ST	95050=US	
						U.S. PATEN	T DOCUMENTS				
		nt Code known)					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
					:- -						
		بح.			FC	REIGN PAT	ENT DOCUMEN	rs			
	No.	Office	Numb	er (if	ent nd Code known)	of Cite	entee or Applicant d Document	Date of Publication of Cited Document MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
KAL	FA	wo	93/202			Burrell et al.		10-14-1			
KAL	FB	wo	94/294			Schweighoffe Picksley et a	Schweighoffer et al.		12-22-1994 02-01-1996		igspace
KAL	FC	1440	201050	46	 	ricksley et a	··	02-01-1	880		-
											+
					 	 				 	+
		<u> </u>			<u> </u>						

02-23-00 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, PAGE 4/6 * RCVD AT 5/19/2004 2:48:37 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):01-56

112/01/20	7
APR 0 7 mgg (g)	•
Please type a plus sign (+) inside this box	

PTO/SB/08A (6-95)
Approved for use through 09/30/98, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO			ent of Commerce				
		Patent and To	rademark Office	Application Number	09/029,327		
UST	OF PRIOR	ART CITE) BY	Filing Date	March 3, 1998		
APPLICANT				First Named Inventor	Tocque et al.		
				Group Art Unit	(635		
	•			Examiner Name	Karen Lacourdere		
Sheet	2	of	2	Attorney Docket Number	ST95050 -US		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.							
KAL	PA	Leng et al., Human oncoprotein MDM2 interacts with the TATA-binding protein in vitro and in vivo, International Journal of Oncology 6: 251-259 (1995)							
KAL	PB	Leveillard et al., The Oncoprotein MDM2 Associates With The TATA-Binding Protein (TBP), Journal of Cellular Biochemistry Supp. 19A (1995)							
KAL	PC	Chen et al., Mapping of the p53 and mdm-2 Interaction Domains, Molecular & Cellular Biology, 13(7): 4107-4114 (1993)							
)							

EXAMINER SIGNATURE LALER	Lacourciere	DATE CONSIDERED	01-23-00	
TWANDED IN THE STANDARD CORRESPONDE	subether or not citation is i	a conformance with MPFP 6	109. Draw line through cits	tion it noi in

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Palent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PAGE 5/6* RCVD AT 5/19/2004 2:48:37 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729306 * CSID: * DURATION (mm-ss):01-56

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.